expand_moreexpand_lessexpand_moreexpand_less
|
 |
Mike FeuzAmerican Thinker |
Europe shows what can happen when countries let bureaucratic procedures take precedence over the well-being of people suffering from rare diseases.
For years, pharmaceutical executives have insisted that drug prices are out of their hands. Government red tape, research costs, and reimbursement...
login
who are we?
contact us
qosheapp
